Background Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a cause of chronic liver disease, often resulting in liver cirrhosis, portal hypertension, and hepatocellular carcinoma damaging outcomes. Alanine transaminase (ALT) and aspartate aminotransferase (AST) are indicators of hepatocellular injury. Several studies have demonstrated that high ALT levels are correlated with higher nonalcoholic steatohepatitis (NASH) risk. The aim was to determine the correlation of serum alanine aminotransferase and aspartate transaminase with liver stiffness in Vietnamese patients with NAFLD. Patients and Methods The study included 18 to 80 years old patients diagnosed with fatty liver on ultrasound at the University of Medical Center (UMC) liver clinic. Liver stiffness was measured using transient elastography. The histopathological, demographic, and laboratory data of the participants were also collected. The baseline and clinical characteristics of NAFLD patients were stratified by serum ALT levels. Results There were 138 NAFLD patients, including 82 men (59.4%) and 56 women (40.6%) (mean ± SD age of 41 ± 11 years). Liver fibrosis (F0) between the two groups showed no significant difference (p = 0.469). Similarly, no difference was found in the mild fibrosis level (F2) of the two groups of patients (p = 0.371). ALT level was significantly higher in NAFLD patients with advanced fibrosis (F3, F4) (3.2% vs 15.9%, p = 0.0013; 3.2% vs 13.2%, p = 0.0047, respectively). NAFLD patients with mild to moderate fibrosis (F1-F2) were detected at 59 U/L cut-off value with 67% sensitivity and 51% specificity. However, severe fibrosis and/or cirrhosis patients (F3-F4) had a cut-off value of 81 U/L with 53% sensitivity and 67% specificity in patients. Conclusion Using ALT level as a marker for severe NAFLD would consider high-risk patients as mild cases, even though there is still the risk of progressive and severe hepatic disease. Our study underlines the small contribution of ALT as an independent factor for detecting NAFLD severity.

Background and Aim: The aim of this study was to investigate the antibiotics used in patients with acute pancreatitis and evaluate their appropriateness. Methods: We conducted a descriptive cross-sectional study on 136 patients aged 18 years or older who were diagnosed with acute pancreatitis and admitted to a national hospital in Ho Chi Minh City from January 2017 to December 2018. Medical records of patients were reviewed for data analysis, including epidemiological characteristics, pathological characteristics, treatment methods, and treatment effectiveness. Results: There were 69.9% men and 30.1% women with a median age of 49.9 years. The most common etiologies included alcohol (21.3%), gallstones (23.6%), and hypertriglyceridemia (19.9%). The proportions of mild, moderate, and severe disease were 54.4, 39.0, and 6.6%, respectively. Antibiotics were given in 52.2% of patients. Although antibiotic prophylaxis was not recommended, 23.5% of cases used prophylactic antibiotics when there were no suspicion or evidence of infection. Conclusions: Our study suggests that it is necessary to optimize the appropriateness of antibiotic indications for patients with acute pancreatitis.

Background and AimIrritable bowel syndrome (IBS) is associated with repetitive gastrointestinal symptoms that greatly reduce the patient's quality of life (QoL). Training regarding IBS‐related knowledge, medication adherence, lifestyle, and diet adjustments has been demonstrated to strengthen patient QoL. The aim of this study was to evaluate the effectiveness of an educational intervention carried out by clinical pharmacists to improve the QoL of patients with IBS.MethodsOur research included data collected at the University Medical Center, Ho Chi Minh City, from April 2018 to December 2018, and was designed as a randomized controlled clinical trial. Patients with IBS were randomized into an intervention group (IG) and nonintervention group (NIG). The intervention program included training about IBS‐related knowledge, the importance of medication adherence, symptom recognition, lifestyle, and diet adjustments. Participants were followed up by monthly telephone calls. The outcome was the change in patient QoL scores (IBS‐QoL) 8 weeks after they took part in the research.ResultsOf 273 patients in the trial, there were 132 patients in the IG cohort and 141 in the NIG cohort. At 8 weeks, IG QoL score changes were statistically higher than those of NIG: 20.1 ± 12.1 (IG) versus 13.2 ± 13.4 (NIG). Furthermore, pharmacist intervention played an important role in increasing QoL after 8 weeks, as confirmed by multivariate regression analysis (B = 5.9; 95% confidence interval 2.4–9.4, P = 0.001).ConclusionsPatient education, lifestyle, and dietary intervention, administered by clinical pharmacists, improves IBS‐QoL compared to standard medical therapy over 8 weeks.